Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia

被引：0
|
作者：
Burnett, John R. [1 ]
机构：
[1] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, PathW Lab Med WA, Perth, WA 6847, Australia
来源：
CURRENT OPINION IN MOLECULAR THERAPEUTICS | 2006年 / 8卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase II clinical trials, while phase I trials are underway with an oral formulation of the drug.
引用
收藏
页码：461 / 467
页数：7
相关论文
共 50 条
  • [1] Isis-301012 - Antisense inhibitor of apolipoprotein B treatment of lipoprotein disorders
    Wang, Y.
    DRUGS OF THE FUTURE, 2007, 32 (08) : 699 - 702
  • [2] ISIS 301012 gene therapy for hypercholesterolemia: Sense, antisense, or nonsense?
    Ito, Matthew K.
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (10) : 1669 - 1678
  • [3] Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012
    Akdim, Fatima
    El Harchaoui, Karim
    Stroes, Erik S. G.
    Kastelein, John J. P.
    FUTURE LIPIDOLOGY, 2007, 2 (04): : 387 - 393
  • [4] Statin-like, dose-dependent reductions in LDL-C and apoB with ISIS 301012, an antisense inhibitor of apoB, in subjects with polygenic hypercholesterolemia
    Stein, E.
    Bradley, J. D.
    Chuang, E.
    Wedel, M. K.
    Su, J.
    Geary, R.
    Yu, R.
    Tribble, D.
    Kastelein, J. P.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 7 - 7
  • [5] BIOGEN AND ISIS JOIN FOR ANTISENSE DRUG
    不详
    CHEMICAL & ENGINEERING NEWS, 2012, 90 (28) : 15 - 15
  • [6] Dose-dependent reductions in LDL-C with ISIS 301012, an antisense inhibitor of apolipoprotein B
    Tribble, D.
    Wedel, M.
    Baker, B.
    Stein, E.
    Fuhr, R.
    Jukema, J.
    Sijbrands, E.
    Trip, M.
    Visseren, F.
    Weiss, R.
    Akdim, F.
    Kastelein, J.
    RECENT ADVANCES IN CARDIOVASCULAR DISEASE: PROCEEDINGS OF THE 13TH WORLD CONGRESS HEART DISEASE, 2007, : 255 - +
  • [7] Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
    Yu, Rosie Z.
    Kim, Tae-Won
    Hong, An
    Watanabe, Tanya A.
    Gaus, Hans J.
    Geary, Richard S.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (03) : 460 - 468
  • [8] Antisense oligonucleotide drug design
    Schiavone, N
    Donnini, M
    Nicolin, A
    Capaccioli, S
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (07) : 769 - 784
  • [9] TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT WITH AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF TTR (ISIS-TTR RX)
    Benson, M. D.
    Ackermann, E. J.
    Monia, B.
    CARDIOLOGY, 2015, 131 : 233 - 233
  • [10] ISIS ANTISENSE DRUG WINS FDA APPROVAL
    不详
    CHEMICAL & ENGINEERING NEWS, 2013, 91 (05) : 14 - 14
12345